Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Serodus ASA
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
Initial research about inhibiting CD47 signaling on tumor cells has meant a focus on oncology drug development. New research shows that inhibiting this cell surface molecule could be used to treat atherosclerosis.
Pre Diagnostics AS is a 2.5-year-old Oslo company developing a blood-based test performed by a GP and sent to a lab for early Alzheimer’s diagnosis.
Improvements in targeting the sources of aberrant cardiac rhythms may open the heart up to new therapies. In this issue, we profile four start-ups focused on developing treatments for AF and other arrhythimas: Acesion Pharma, ChanRx, Milestone Pharmaceuticals and Serodus.
- Other Names / Subsidiaries
- Phlogo ApS
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.